title: Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer.
abstract: Tumor progression and metastasis are promoted by the remodeling of organized tissue architecture and engagement of molecular interactions that support tumor cell passage through endothelial barriers. Prostate tumor cells that secrete and turn over excessive quantities of pericellular hyaluronan (HA) exhibit accelerated growth kinetics and spontaneous lymph node metastasis in mice. The HA receptor for endocytosis (HARE) is an endocytic clearance receptor for HA in the liver that is also highly expressed in sinusoidal endothelium of lymph nodes and bone marrow, which are frequent sites of prostate cancer metastasis. In our study, we tested the hypothesis that HARE can act as an endothelial receptor for metastatic tumor cells with pericellular HA. In an orthotopic mouse model of prostate cancer, we delivered a monoclonal antibody against HARE that specifically blocks HA binding and internalization. This treatment fully blocked the formation of metastatic tumors in lymph nodes. No effects on primary tumor growth were observed and the antibody did not induce toxic outcomes in any other tissue. Our results implicate HARE for the first time in potentiation of tumor metastasis and suggest a novel mechanism by which tumor cell-associated HA could promote tissue-specific dissemination. "Published 2012 Wiley Periodicals, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."
authors.affiliation: Department of Biochemistry, University of Nebraska, Lincoln, NE 68588, USA. msimpson2@unl.edu
authors.forename: Melanie A
authors.initials: MA
authors.lastname: Simpson
authors.forename: Janet A
authors.initials: JA
authors.lastname: Weigel
authors.forename: Paul H
authors.initials: PH
authors.lastname: Weigel
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015816:Cell Adhesion Molecules, Neuronal / Q000037:antagonists & inhibitors* / Q000276:immunology; D004705:Endocytosis; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D008198:Lymph Nodes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D015816:Cell Adhesion Molecules, Neuronal; C449927:STAB2 protein, human; D006820:Hyaluronic Acid